Gastrointestinal Cancer News

Precolonoscopy office visits to a gastroenterologist may increase unnecessary costs associated with the procedure, according to an analysis of billing data.

Immigrants are considerably underserved in terms of health care in the United States.

SAN FRANCISCO — Vincent J. Picozzi, MD, a medical oncologist from Virginia Mason Medical Center in Seattle, reacts to results from the phase 3 NETTER-1 trial presented at the Gastrointestinal Cancers Symposium.

The association between the risk for colorectal cancer and plasma 25-hydroxyvitamin D varies depending on the degree of intratumoral periglandular reaction, according to results of a nested case-control study. High-level plasma 25-hydroxyvitamin D was linked with a decrease in the risk for tumors with high-level reaction, but not tumors with low-level reaction.

Rare dihydropyrimidine dehydrogenase gene variants appeared to significantly increase the incidence of high-grade fluorouracil-related adverse events among patients with stage III colon cancer, according to a secondary analysis of a randomized trial.

In this video with Healio.com, David P. Ryan, MD, chief of hematology/oncology and medical oncologist at Massachusetts General Hospital, highlights issues at the forefront of colorectal cancer.

Filing for bankruptcy protection after a cancer diagnosis appeared associated with an increased risk for death, according to the results of a registry study.

The genomic profiling of cancers, including colorectal cancer, has resulted in a “very exciting time in solid tumor oncology,” according to David H. Ilson, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center and a professor of medicine at Weill Cornell Medical College.

By 2030, it is estimated that 1 in 4 patients with rectal cancer and 1 in 9 patients with colon cancer will be under the age of 50 years, according to George J. Chang, MD, professor of surgical oncology and health services research and chief of the section of colon and rectal surgery at The University of Texas MD Anderson Cancer Center.

SAN FRANCISCO — Daniel Chang, MD, associate professor of radiation oncology at Stanford University, discusses the phase 3 ACCORD randomized trial data presented at the Gastrointestinal Cancers Symposium, which compared radiation with 5-fluorouracil (5-FU) vs. radiation with oxaliplatin and 5-FU in rectal cancer.